References
- Fratantoni J. C. Points to consider in the safety evaluation of hemoglobin based oxygen carriers. Transfusion 1991; 31(4)369–371
- Ning J., Chang T.M.S. Effects of stroma-free hemoglobin and polyhemoglobin on blood cells, complement activation and coagulation factors in rats (abs). J. Biomaterials, Artificial Cells and Artificial Organs 1987; 15: 380
- Feola M., Simoni J., Canizaro P. C. Complement activation and the toxicity of stroma-free hemoglobin solution in primates. Cir. Shock 1988; 52: 275–290
- Chang T. M.S., Lister C. A screening test of modified hemoglobin blood substitute before clinical use in patients-based on complement activation of human plasma. Int. J. Biomaterials, Artificial Cells and Artificial Organs 1990; 18(5)693–702
- Chang T. M.S., Lister C. A preclinical screening test for modified hemoglobin to bridge the gap between animal safety studies and use in human. Biomaterials, Artificial Cells and Immobilization Biotechnology 1992; 20(2-4)565–573
- Chang T. M.S., Lister C. 1993 Screening test for modified hmoglobin blood substitute before use in human. US Patent No. 5 April 6, 1993; 200: 323, (assigned to McGill University)
- Chang T. M.S., Lister C., Wong L. T., Er S. S. The use of a preclinical screening test based on C3a activation of human plasma in industrial production of o-raffinose polymerized hemoglobin. Abstract, V International Symposium on Blood Substitutes, San Diego 1993
- Chang T. M.S., Yu W. P. British Provisional Patent Application. 1992 Biodegradable polymer membrane containing hemoglobin for blood substitute. UK September 14, 1992; 9219426: 5